Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.52 |
| ▸ | TDO2 | P48775 | 1/20 | 0.52 |
| ▸ | MTOR | P42345 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.43 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.43 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL792296 | 0.93 | ACHE (0.48) | IDO1TDO2MTORSLC6A4SLC6A2 | |
| Ammonia Solution, Strong SCHEMBL6000669 | 0.91 | ACHE (0.46) | IDO1TDO2MTORSLC6A4SLC6A2 | |
| SCHEMBL25922472 | 0.89 | DAO (0.42) | IDO1TDO2HDAC4HDAC7HDAC5 | |
| SCHEMBL16191280 | 0.86 | ACHE (0.48) | IDO1TDO2SLC6A4SLC6A2HDAC4 | |
| SCHEMBL23817077 | 0.84 | IDO1 (0.50) | IDO1TDO2OPRM1OPRD1OPRK1 | |
| SCHEMBL2210935 | 0.84 | TYR (0.47) | KDM4E | |
| SCHEMBL15429373 | 0.83 | ACHE (0.61) | IDO1TDO2HDAC4HDAC7HDAC5 | |
| Ammonia Solution, Strong SCHEMBL5998797 | 0.83 | ROCK2 (0.41) | IDO1TDO2SLC6A4SLC6A2HDAC4 | |
| SCHEMBL27969245 | 0.81 | TAAR1 (0.51) | IDO1TDO2SLC6A4SLC6A2AOC3 | |
| SCHEMBL17071841 | 0.79 | NPC1 (0.47) | SLC6A4NFE2L2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9694002-B2 | Substituted benzamides and methods of use thereof | GENENTECH, INC. (US) | 2017-07-04 | — | — | US | disclosed |
| US-20170087136-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-03-30 | — | — | US | disclosed |
| CN-104025364-B | Organic bath and organic bath accumulator | 吉坤日矿日石能源株式会社 | 2017-03-08 | — | — | CN | disclosed |
| US-9546164-B2 | Substituted benzamides and methods of use thereof | GENENTECH, INC. (US) | 2017-01-17 | — | — | US | disclosed |
| US-20150252038-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | XENON PHARMACEUTICALS INC. (CA) | 2015-09-10 | — | — | US | disclosed |
| US-20150004484-A1 | ORGANIC ELECTROLYTE AND ORGANIC ELECTROLYTE STORAGE BATTERY | JX NIPPON OIL & ENERGY CORPORATION (JP) | 2015-01-01 | — | — | US | disclosed |
| US-20140370375-A1 | ORGANIC ELECTROLYTE AND ORGANIC ELECTROLYTE STORAGE BATTERY | JX NIPPON OIL & ENERGY CORPORATION (JP) | 2014-12-18 | — | — | US | disclosed |
| EP-2797153-A1 | ORGANIC ELECTROLYTE, AND ORGANIC ELECTROLYTE STORAGE BATTERY | JX Nippon Oil & Energy Corporation (JP) | 2014-10-29 | — | — | EP | disclosed |
| EP-2797154-A1 | ORGANIC ELECTROLYTE, AND ORGANIC ELECTROLYTE STORAGE BATTERY | JX Nippon Oil & Energy Corporation (JP) | 2014-10-29 | — | — | EP | disclosed |
| CN-104025364-A | Organic electrolyte, and organic electrolyte storage battery | JX NIPPON OIL & ENERGY CORP | 2014-09-03 | — | — | CN | disclosed |
| CN-104011928-A | Organic electrolyte, and organic electrolyte storage battery | JX NIPPON OIL & ENERGY CORP | 2014-08-27 | — | — | CN | disclosed |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | NGF, DCX, BDNF | IDO1 1319/4885TDO2 4111/4885MTOR 1588/4885 |
| US-20150252038-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | BRIX1, RDX, RRM1 | IDO1 2828/4885TDO2 3591/4885MTOR 3897/4885 |
| US-20170087136-A1 | SUBSTITUTED BENZAMIDES AND METHODS OF USE THEREOF | C1R, SRR, PNISR | IDO1 2555/4885TDO2 3618/4885MTOR 3795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.